.[ 5 ] All of these mechanisms may help to explain the cardiovascular benefits observed.[ 11 , 12 ] The DAPA-HF and the EMPEROR-Reduced ( NCT03057977 ) trials showed statistically significant reductions in HF hospitalisation, regardless of history of diabetes.[ 34 ] However, the change in mortality did not reach statistical significance in EMPEROR-Reduced.[ 35 ] The cardioprotective mechanisms independent of glucose lowering are still not fully understood.
1
—
—